Sarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) is up 82% after re-opening on accelerated approval for eteplirsen
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta's (SRPT) Exondys 51 covered by Humana (HUM) with prior authorization - Bloomberg
- Stocks with Implied Volatility Movement
- Option volume flows
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!